ClinicalTrials.gg
CompletedNCT06929156Updated Oct 13, 2026

A Study of BGM0504 in Healthy Participants and Participants With Impaired Renal Function

A Phase 1 interventional study of BGM0504 and BGM0504 in Type 2 Diabetes Mellitus (T2DM) and Overweight or Obese, sponsored by BrightGene Bio-Medical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by BrightGene Bio-Medical Technology Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 909 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 228 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Enrollment
657th of 767
34 · median 199
Started
2025
with 79 others
Phase 1
122 of 909
12 open now
Registered
739th of 909
by date

Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 657th largest by enrollment of the 767 interventional ones that give a count, is one of 80 that started in 2025, is one of 122 in phase 1, and was the 739th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 909 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to assess how fast BGM0504 gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)
  • Overweight or Obese
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • √ Age 18-65 years on the date of signing (inclusive);

    • (BMI) within the range of 19.0-30.0 kg/m2 (inclusive);.
    • Stable renal function, assessed by two during screening (apart at least 3 days);
    • Diagnosed as stable, chronic renal disease for at least 3 months.
    • Renal function, assessed by estimated glomerular filtration rate at screening (eGFR):

      1. Normal renal function: 90-129 mL/min (inclusive);
      2. Mild impairment: 60-89 mL/min (inclusive);
      3. Moderate impairment: 30-59 mL/min (inclusive);
      4. Severe impairment: 15-29 mL/min (inclusive);

Exclusion criteria

Exclusion Criteria:

  • ● Allergic constitution includes severe drug allergy or history of drug allergy;

    • Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2; Have a history or presence of pancreatitis;
    • Participants in clinical trials of any drug or medical device in the 3 months prior to screening;.
    • Suspected or confirmed history of alcohol or drug abuse;
    • surface antigen (HBsAg), antibody detection, virus antibody (HCVAb), treponema pallidum specific antibody detection, positive;
    • Donation or loss of 200 mL or more of blood within 3 months prior to screening, or blood donation during screening or within 1 months after the end of the trial;
    • Pregnant or Breast-feeding women;
    • The investigator considers that the participant has any other factors that would make it inappropriate to participate in this study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    A group (Healthy Control)

    Drug: BGM0504

  • Experimental
    B group (Mild Renal Impairment)

    Drug: BGM0504

  • Experimental
    C group (Moderate Renal Impairment)

    Drug: BGM0504

  • Experimental
    D group (Severe Renal Impairment)

    Drug: BGM0504

Interventions

  • Receive a single dose of BGM0504 injection

  • Receive a single dose of BGM0504 injection

  • Receive a single dose of BGM0504 injection

  • Receive a single dose of BGM0504 injection

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration Versus Time Curve (AUC) of BGM0504 From Time Zero to Tlast (AUC0-t)

    Area Under the Concentration Versus Time Curve (AUC) of BGM0504 From Time Zero to Tlast (AUC0-t)

    Time frame: Start of Treatment up to Day 29

  2. Maximum Concentration of BGM0504 (Cmax)

    Maximum Concentration of BGM0504 (Cmax)

    Time frame: Start of Treatment up to Day 29

  3. Area Under the Concentration Versus Time Curve (AUC) of BGM0504 From Time Zero to Infinity (AUC0-inf)

    Area Under the Concentration Versus Time Curve (AUC) of BGM0504 From Time Zero to Infinity (AUC0-inf)

    Time frame: Start of Treatment up to Day 29

Secondary outcomes

  1. Time to maximum concentration (Tmax)

    Time to maximum concentration (Tmax)

    Time frame: Start of Treatment up to Day 29

  2. Apparent terminal half-life (t1/2)

    Apparent terminal half-life (t1/2)

    Time frame: Start of Treatment up to Day 29

  3. Apparent clearance (CL/F)

    Apparent clearance (CL/F)

    Time frame: Start of Treatment up to Day 29

  4. Incidence and severity of adverse events

    Incidence and severity of adverse events

    Time frame: Screening period up to Day 29

07

Study locations

1 site
  • The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital, Shandong Province)
    Jinan, Shandong 650100, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Dec 2025, 7 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 7 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2025
First posted
Apr 16, 2025
StartActual
May 6, 2025
Primary completionActual
Dec 25, 2025
CompletionActual
Dec 25, 2025
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06929156
Responsible party
Sponsor
First posted
Apr 16, 2025
Start date
May 6, 2025
Primary completion
Dec 25, 2025
Completion
Dec 25, 2025
Last update
Oct 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BGM0504

Start the discussion